Study study type PathologyT1T0Patientssample sizesROB Results

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg)
E1609 (ipi10), 2020
  NCT01274338
RCTmML - NA - all populationipilimumab 10 mg/kgHDI high dose of interferon alphamelanoma of cutaneous or unknown primary origin (AJCC 7th edition stage IIIB, IIIC, or IV [M1a or M1b]) who were rendered disease free surgically. No priorsystemic adjuvant therapy was permitted.511 / 636high
inconclusive
  • inconclusive 12 % decrease in deaths (OS) (PE)
  • inconclusive 16 % decrease in RFS/DFS (PE)
ipilimumab alone
E1609 (ipi3), 2020
  NCT01274338
RCTmML - NA - all populationipilimumab 3 mg/kgHDI high dose of interferon alphamelanoma of cutaneous or unknown primary origin (AJCC 7th edition stage IIIB, IIIC, or IV [M1a or M1b]) who were rendered disease free surgically. No priorsystemic adjuvant therapy was permitted.523 / 636high
conclusif
  • demonstrated 22 % decrease in deaths (OS) (PE)
  • inconclusive 15 % decrease in RFS/DFS (PE)
versus placebo
Ipilimumab (10 mg/kg)
EORTC 18071, 2015
  NCT00636168
RCTmML - NA - all populationipilimumab placebo patients with completely resected high-risk stage III melanoma who had not received previous systemic therapy for melanoma475 / 476low
conclusif
  • demonstrated 28 % decrease in deaths (OS) (PE)
  • demonstrated 25 % decrease in RFS/DFS (PE)
  • demonstrated 24 % decrease in MFS (PE)
  • suggested 27 % decrease in deaths (OS) (extension)
  • more...